Market closed

Amneal Pharmaceuticals/$AMRX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Amneal Pharmaceuticals

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Ticker

$AMRX
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
Bridgewater, United States

Employees

7,850
Website
amneal.com

AMRX Metrics

BasicAdvanced
$2.4B
-
-$0.63
1.17
-

$2.4B

1.17

$9.23

$5.01

1.1M

1.382

0.758

-6,721.021

-7,852.319

1.34%

6.03%

-185.77%

0.857

-26.03

-1.65

10.021

12.32%

-1,144.53%

9.05%

90.23%

What the Analysts think about AMRX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Amneal Pharmaceuticals stock.

AMRX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AMRX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

AMRX News

AllArticlesVideos
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Business Wire·2 months ago
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Seeking Alpha·2 months ago
Amneal Reports Third Quarter 2024 Financial Results

Amneal Reports Third Quarter 2024 Financial Results

Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AMRX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Amneal Pharmaceuticals stock?

Amneal Pharmaceuticals (AMRX) has a market cap of $2.4B as of January 15, 2025.

What is the P/E ratio for Amneal Pharmaceuticals stock?

The price to earnings (P/E) ratio for Amneal Pharmaceuticals (AMRX) stock is 0 as of January 15, 2025.

Does Amneal Pharmaceuticals stock pay dividends?

No, Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Amneal Pharmaceuticals dividend payment date?

Amneal Pharmaceuticals (AMRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Amneal Pharmaceuticals?

Amneal Pharmaceuticals (AMRX) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.